Trkb Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TrkB (Tropomyosin Receptor Kinase B) is the high-affinity receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4. This receptor tyrosine kinase is essential for synaptic plasticity, learning, memory, and neuronal survival. TrkB is a major therapeutic target for Alzheimer's disease, Parkinson's disease, and depression.
| Property |
Value |
| Protein Name |
TrkB |
| Gene Symbol |
NTRK2 |
| UniProt ID |
Q16620 |
| Molecular Weight |
145 kDa (822 amino acids) |
| Subcellular Localization |
Cell membrane, endosomes, synapses |
| Protein Family |
Trk family (TrkA, TrkB, TrkC) |
- TrkB.FL (full-length): Functional receptor with tyrosine kinase domain
- TrkB.T1 (truncated): Dominant-negative, lacks kinase domain
- TrkB.T2 (truncated): Alternative splice variant
- Extracellular domain: Leucine-rich motifs, Ig-like domains (ligand binding)
- Transmembrane domain: Single pass membrane
- Cytoplasmic domain: Tyrosine kinase domain, C-terminal tail
- BDNF/NT-4 receptor: High-affinity binding activates signaling
- Synaptic plasticity: Promotes LTP, dendritic spine formation
- Learning and memory: Critical for hippocampus-dependent memory
- Neuronal survival: PI3K/Akt, MAPK/ERK, PLCγ pathway activation
- Neurogenesis: Supports neural progenitor cell function
- BDNF/TrkB signaling impaired in AD brain
- Reduced TrkB expression in hippocampus
- Therapeutic potential: TrkB agonists
- BDNF therapy in clinical trials
- Neuroprotective for dopaminergic neurons
- AAV-BDNF/TrkB approaches in development
- May protect against alpha-synuclein toxicity
- Antidepressant effects of BDNF/TrkB signaling
- Ketamine acts via TrkB
- Genetic variants associated with depression
- Rett syndrome: Dysregulated TrkB signaling
- Huntington's Disease: BDNF/TrkB deficit
- Epilepsy: Altered expression
| Approach |
Status |
Description |
| AAV-BDNF |
Clinical trials |
Gene therapy for AD |
| TrkB agonists |
Research |
Small molecule BDNF mimetics |
| 7,8-DHF |
Research |
TrkB activator |
| Antibody approaches |
Preclinical |
TrkB-activating antibodies |
- Huang EJ, Reichardt LF. (2001). Neurotrophins: roles in neuronal development. Annu Rev Neurosci. 24:677-736. https://doi.org/10.1146/annurev.neuro.24.1.677
- Lu B, et al. (2013). BDNF-based synaptic repair. Nat Rev Neurosci. 14(6):401-16. https://doi.org/10.1038/nrn3505
- Autry AE, Monteggia LM. (2012). Brain-derived neurotrophic factor. Pharmacol Rev. 64(2):238-58. https://doi.org/10.1124/pr.111.005108
- Murer MG, et al. (2001). Brain-derived neurotrophic factor. J Neurol Sci. 191(1-2):21-4. https://doi.org/10.1016/s0022-510x(01)00604-3
The study of Trkb Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] TrkB signaling in neuroprotection. PMID:24790033
TrkB agonists such as 7,8-DHF and BDNF mimetics are being developed for AD, PD, and stroke. These agents promote neuronal survival and synaptic plasticity.
TrkB activation can modulate AMPA receptor trafficking, potentially benefiting synaptic function in neurodegenerative disorders.
TrkB signaling in the hippocampus mediates antidepressant-like behaviors, making it a target for depression treatment in neurodegenerative disease patients.
- Development of brain-penetrant TrkB agonists
- Understanding TrkB isoform-specific functions
- TrkB-BDNF axis in glial cells
- Biomarkers of TrkB signaling activity